Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma

Hepatic artery infusion chemotherapy (HAIC) is a locoregional therapy commonly used in hepatocellular carcinoma (HCC), with high response rates and minimal impairment of liver function reported. Transarterial chemoembolization (TACE) and transarterial embolization (TAE) are also commonly used in HCC, with high response rates reported yet carry risks of impairing liver function after repeated embolization with a definitive embolic agent. On the other hand, lipiodol used in TACE/TAE has transient and plastic embolization effects on the tumor in contrast to the long-lasting embolization effect of

Trial Details

NCT ID
NCT06632717
Phase
PHASE2
Sponsor
National Taiwan University Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Cisplatin
  • 5-fluorouracil
  • Lipiodol embolization
Locations (sample)
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Histologically or clinically (typical HCC imaging findings by multi-phase CT or MRI) diagnosed HCC.
  • Barcelona Clinic Liver Cancer (BCLC) Stage C disease (liver confined disease or liver predominant disease, as determined by the investigator) or BC…
  • Archival tissue available (\< 2 years) or agree to have biopsy tissue at baseline

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →